medigraphic.com
ISSN 1817-5996 (Electronic)

2022, Number 2

<< Back Next >>

Rev Cub de Reu 2022; 24 (2)

New landscape for pediatric rheumatic diseases

Cazar CMJ, Pino FPE, Moya RKS, Muñiz VVA

Language: Spanish
References: 30
Page:
PDF size: 458.03 Kb.


ABSTRACT

Introduction: The effective treatment of postoperative pain is today a challenge for anesthetists, rheumatologists, orthopedic surgeons, surgeons and researchers of various specialties, who constantly propose protocols based on scientific evidence.
Objective: Reflect and open the debate regarding the role of anesthesia in the relief of pain of rheumatological origin.
Development: In Rheumatology, it is recommended, in all patients with chronic rheumatic pain, to calculate the intensity of the pain, both for the first choice of the analgesic treatment and for the measurement of the response. And, for this, several methods of quantification have been proposed.
Conclusions: Diagnostic management and multidisciplinary treatment preside when this type of case is examined, since it is the only way to identify the origin of pain and provide prudent relief. In general, patients respond to conservative treatment and only a small group will need invasive anesthetic techniques.


REFERENCES

  1. Nadareishvi Li Z, Michaud K, Hallenbeck JM, Wolfe F. Cardiovascular, rheumatologic, and pharmacologic predictors of stroke in patients with rheumatoid arthritis: A nested, case-controL study. Arthritis Care & Research. 2008;59:1090-6.

  2. Holmqvist ME, Wedrén S, Jacobsson LTH, Klareskog L, Nyberg F, Rantapaa-Dahlqvist S, et al. Rapid increase in myocardial infarction risk following diagnosis of rheumatoid arthritis amongst patients diagnosed between 1995 and 2006. Journal of Internal Medicine. Dec 2010;268(6):578-85.

  3. Sinicato NA, da Silva Cardoso PA, Appenzeller S. Risk factors in cardiovascular disease in systemic Lupus erythematosus. Curr CardioL Rev. Feb 2013;9(1):15-9.

  4. Ungprasert P, Raksasuk S. Increased Risk of Incident Chronic Kidney Disease Among Patients with Rheumatoid Arthritis: A Systematic Review and Meta-AnaLysis of Cohort Studies. Presentation. ACR/ARHP AnnuaL Meeting. 2018

  5. Raimundo K, Solomon JJ, Olson AL, Kong AM, Cole AL, Fischer A, et al. Rheumatoid Arthritis-Interstitial Lung Disease in the United States: Prevalence, Incidence, and Heathcare Costs and MortaLity. The Journal of Rheumatology. April 2019;46(4):360-9.

  6. Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al. International league of associations for rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31:390-2.

  7. Ravelli A, Minoia F, Davi S, Horne A, Bovis F, Pistorio A, et al. Classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: A European League Against Rheumatism/American College of Rheumatology/paediatric rheumatology international trials organisation collaborative initiative. Ann Rheum Dis. 2016;75:481-9.

  8. Barbour KE, Helmick CG, Boring M, Brady TJ. Vital Signs: Prevalence of Doctor Diagnosed Arthritis and Arthritis Attributable Activity Limitation - United States, 2013-2015. Morb Mortal Wkly Rep. March 2017;66:246-53.

  9. Jafarzadeh SR, Felson DT. Updated estimates suggest a much higher prevalence of arthritis in US aduts than previous ones. Arthritis Rheumato. February 2018;70(2):185-92.

  10. Sacks JJ, Helmick CG, Luo YH, Ilowite NT, Bowyer S. Prevalence of and annual ambulatory health care visits for pediatric arthritis and other rheumatologic conditions in the United States in 2001-2004. Arthritis Rheum. 2007;57:1439-45.

  11. Monti S, Montecucco C, Bugatti S, Caporali R. Rheumatoid arthritis treatment: the earlier the better to prevent joint damage. RMD Open. 2015;1(Suppl 1).

  12. Zou LX, Lu MP, Jung LKL. Current status and recent advances on the use of ultrasonography in pediatric rheumatic diseases. World J Pediatr. 2019. https://doi.org/10.1007/s12519-019-00312-912.

  13. Barendregt AM, van Gulik EC, Lavini C, Nusman CM, van den Berg JM, Schonenberg-Meinema D, et al. Diffusion-weighted imaging for assessment of synovial inflammation in juvenile idiopathic arthritis: a promising imaging biomarker as an alternative to gadolinium-based contrast agents. Eur Radiol. 2017;27:4889-99.

  14. Malattia C, Damasio MB, Basso C, Verri A, Magnaguagno F, Viola S, et al. Dynamic contrast-enhanced magnetic resonance imaging in the assessment of disease activity in patients with juvenile idiopathic arthritis. Rheumatology (Oxford). 2010;49:178-85.

  15. McCann LJ, Juggins AD, Maillard SM, Wedderburn LR, David- son JE, Murray KJ, et al. The Juvenile Dermatomyositis National Registry and Repository (UK and Ireland) clinical characteristics of children recruited within the first 5 years. Rheumatology (Oxford). 2006;45:1255-60.

  16. Thyoka M, Adekunle O, Pilkington C, Walters S, Arthurs OJ, Humphries P, et al. Introduction of a novel magnetic resonance imaging-based scoring system for assessing disease activity in children with juvenile dermatomyositis. Rheumatology (Oxford). 2018;57:1661-8.

  17. Eutsler EP, Horton DB, Epelman M, Finkel T, Averill LW. Musculoskeletal MRI findings of juvenile localized scleroderma. Pediatr Radiol. 2017;47:442-9.

  18. Neubauer H, Evangelista L, Morbach H, Girschick H, Prelog M, Kostler H. Diffusion-weighted MRI of bone marrow oedema, soft tissue oedema and synovitis in paediatric patients: feasibility and initial experience. Pediatr Rheumatol J. 2012;10:20.

  19. Li M, Sauer A, Holl-Wieden A, Pabst T, Neubauer HA. Diagnostic value of diffusion-weighted MRI for imaging synovitis in pediatric patients with inflammatory conditions of the knee joint. World J Pediatr. 2019. DOI: https://doi.org/10.1007/s12519-019-00232-819.

  20. Moncrieffe H, Ursu S, Holzinger D, Patrick F, Kassoumeri L, Wade A, et al. A subgroup of juvenile idiopathic arthritis patients who respond well to methotrexate are identified by the serum biomarker MRP8/14 protein. Rheumatology (Oxford). 2013;52:1467-76.

  21. Giancane G, Consolaro A, Lanni S, Davi S, Schiappapietra B, Ravelli A. Juvenile idiopathic arthritis: diagnosis and treatment. Rheumatol Ther. 2016;3:187-207.

  22. Rider LG, Shah M, Mamyrova G, Huber AM, Rice MM, Targoff IN, et al. The myositis autoantibody phenotypes of the juvenile idiopathic inflammatory myopathies. Medicine (Baltimore). 2013;92:223-43.

  23. Wu JQ, Lu MP, Reed AM. Juvenile dermatomyositis: advances in clinical presentation, myositis-specific antibodies and treatment. World J Pediatr. 2019. DOI: https://doi.org/10.1007/s12519-019-00313-823.

  24. Wolstencroft PW, Fiorentino DF. Dermatomyositis clinical and pathological phenotypes associated with myositis-specific autoantibodies. Curr Rheumatol Rep. 2018;20:28.

  25. Arkachaisri T, Vilaiyuk S, Torok KS, Medsger TA Jr. Development and initial validation of the localized scleroderma skin damage index and physician global assessment of disease damage: a proof-of-concept study. Rheumatology (Oxford). 2010;49:373-81.

  26. Saper VE, Chen G, Deutsch GH, Guillerman RP, Birgmeier J, Jagadeesh K, et al. Emergent high fatality lung disease in systemic juvenile arthritis. Ann Rheum Dis. 2019;78:1722-31.

  27. Crow MK, Ronnblom L. Type I interferons in host defence and inflammatory diseases. Lupus Sci Med. 2019;6:e000336.

  28. Wallace DJ, Furie RA, Tanaka Y, Kalunian KC, Mosca M, Petri MA, et al. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet. 2018;392:222-31.

  29. Pan L, Lu MP, Wang JH, Xu M, Yang SR. Immunological pathogenesis and treatment of systemic lupus erythematosus. World J Pediatr. 2019. DOI: https://doi.org/10.1007/s12519-019-00229-329.

  30. Li SC, Zheng RJ. Overview of Juvenile localized scleroderma and its management. World J Pediatr. 2019. DOI: https://doi.org/10.1007/s12519-019-00320-930.




2020     |     www.medigraphic.com